Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with 1H-MRS at 0.5 T

Neurology

Volumn 56, Issue 6, 2001, Pages 737-742

  Antuono, Piero G ^a,b   Jones, Jennifer L ^a   Wang, Yonker ^a   Li, Shi Jiang ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MCW Clinic at Froedtert   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; CREATINE PHOSPHATE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID;

ACCURACY; ADULT; AGED; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; FEMALE; HUMAN; IN VIVO STUDY; MALE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 0035957292     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.6.737     Document Type: Article

References (45)

1. Triggering and execution of neuronal death in brain ischaemia: Two phases of glutamate release by different mechanisms
2. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with 1H MR spectroscopy
3. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced
4. Glutamine as a neurotransmitter precursor: Complementary studies in vivo and in vitro on the synthesis and release of transmitter glutamate and GABA
5. A synaptic model of memory: Longterm potentiation in the hippocampus
6. Role of glutamate and excitotoxicity in neurologic diseases
7. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease
8. Frontotemporal dementia and early Alzheimer disease: Differentiation with frontal lobe H-1 MR spectroscopy
9. Brain tumors: Localized H-1 MR spectroscopy at 0.5 T
10. Detection of glutamate/glutamine resonances by 1H magnetic resonance spectroscopy at 0.5 tesla
11. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of health and human services task force on Alzheimer's disease
12. Pathological verification of ischemic score in differentiation of dementias
13. Use of the Cornell scale in nondemented patients
14. A practical method for grading the cognitive state of patients for the clinician
15. Assessment of older people: Self-maintaining and instrumental activities of daily living
16. Neuroanatomy of Alzheimer's disease
17. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
18. Correction of phase effects produced by eddy currents in solvent suppressed 1H-CSI
19. Proton spectroscopy of human brain: Effects of age and sex
20. Endogenous neurotransmitters amino acids (ENAA) in Alzheimer's disease
21. Excitatory amino acids and Alzheimer's disease
22. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain
23. An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains
24. Regional metabolic alterations in Alzheimer's disease: An in vitro 1H NMR study of the hippocampus and cerebellum
25. Probable Alzheimer disease: Diagnosis with proton MR spectroscopy
26. Contributions of cingulate cortex to two forms of spatial learning and memory
27. Electrolytic but not ibotenic acid lesions of the posterior cingulate cortex produce transitory facilitation of learning in mice
28. Functional heterogeneity in cingulate cortex: The anterior executive and posterior evaluative regions
29. Neural connections of auditory association cortex with the posterior cingulate cortex in the monkey
30. Retrosplenial amnesia
31. Regional pattern of degeneration in Alzheimer's disease: Neuronal loss and histopathological grading
32. NMDA antagonist neurotoxicity: Mechanism and prevention
33. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging
34. Proton magnetic resonance spectroscopy in dementia of Alzheimer type
35. Alzheimer disease and subcortical ischemic vascular dementia: Evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging
36. Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease
37. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions
38. In vivo proton magnetic resonance spectroscopy for metabolic changes of human brain edema
39. Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: Identification of evolving metabolic patterns in relation to dementia and therapy
40. Total brain N-acetylaspartate: A new measure of disease load in MS
41. 1H-MRS evidence of neurodegenerative and excess glutamate and glutamine in ALS medulla
42. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease
43. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells
44. Differentiation of metabolic concentrations between gray and white matter of human brain by in vivo 1H magnetic resonance spectroscopy